May 14, 2020
U.S. Centers for Medicare & Medicaid Services (CMS) Proposes Extending New Technology Add-on Payment (NTAP) Reimbursement for Portola Pharmaceuticals' Andexxa® for Third Year
Apr 16, 2020
Aging Populations Will Increase Demand in the $35,802 Million Antithrombotic Drugs Market, Reports TBRC
Apr 07, 2020
Portola Pharmaceuticals Announces the Establishment of a Permanent J-code for Andexxa by the Centers for Medicare & Medicaid Services, Effective July 1, 2020
Mar 28, 2020
Landmark Phase 3 VOYAGER PAD Study of XARELTO® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity Revascularization
Mar 16, 2020
Portola Pharmaceuticals Announces Results Demonstrating Andexxa® was Associated with Lowest Rate of Mortality in Patients with Multiple Types of Factor Xa Inhibitor-Related Bleeds
Mar 05, 2020
New Data Demonstrates Andexxa® Can Provide a Net Cost Reduction for the Treatment of Intracranial Hemorrhage Associated with Oral Factor Xa Inhibitors
Nov 06, 2019
Portola Pharmaceuticals to Present Multiple Abstracts at the 61st American Society of Hematology (ASH) Annual Meeting
Nov 05, 2019
Portola Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Oct 28, 2019
Portola Pharmaceuticals Presents New Analysis from the ANNEXA-4 Study of its Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Acute Gastrointestinal Bleeding
Sep 20, 2019
XARELTO® (rivaroxaban) Reduces Recurrent Blood Clots and Total Medical Costs in Morbidly Obese Patients
Aug 07, 2019
Portola Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Aug 06, 2019
Portola Launches European Sales of Ondexxya® (Andexanet Alfa) with First Orders in Europe
Aug 05, 2019
New findings provide definitive management guidelines for patients on direct oral anticoagulants with atrial fibrillation undergoing elective procedures or surgeries
Aug 05, 2019
U.S. Centers for Medicare and Medicaid Services (CMS) Increases New Technology Add-On Payment (NTAP) Reimbursement for Portola Pharmaceuticals' Andexxa
Jul 08, 2019
XARELTO® (rivaroxaban) Helps Protect Pediatric Patients from Blood Clots in Late-Breaking Phase 3 EINSTEIN-Jr Study
Dec 14, 2018
Janssen Submits Supplemental New Drug Application (sNDA) to FDA for XARELTO® (rivaroxaban) to Prevent Venous Thromboembolism (VTE) in Acute Medically Ill Patients
Dec 04, 2018
Late-Breaking Clinical Trials Present Clinic-Ready Advances for Non-Malignant Diseases
Oct 11, 2018
U.S. FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Major Cardiovascular Events in Patients with Chronic Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD)
Sep 08, 2018
Aniara Diagnostica Launches http://www.DOACtesting.com Providing Specific Product Information For Direct Oral Anticoagulant Testing
Aug 26, 2018
Researcher finds new blood clot prevention strategy